shironagasukujira/iStock via Getty Images
- AbbVie (NYSE:ABBV) said it has submitted a biologics license application to the U.S. FDA for TrenibotulinumtoxinE (TrenibotE), a treatment aimed at reducing frown lines between the eyebrows, also known as glabellar lines.
- TrenibotE is a botulinum toxin of serotype E, and